Short Summary
Sequenom Inc appealed the rejection of its patent application (No. 3139/DELNP/2012) by the Assistant Controller of Patents and Designs, which held it non-patentable under Section 3(i) of the Patents Act, 1970. The appellant argued that the invention was a screening test, not a diagnostic test, while the respondent relied on the broad definition of 'Pre-Natal Diagnostic Test' under the PCPNDT Act.
Detailed Summary
In the world of medical innovation, the difference between a screening test and a diagnostic test might seem like a technicality. But in the patent world, that distinction can be the difference between owning your invention and watching it slip into the public domain. The case of Sequenom Inc versus the Controller of Patents brings this exact tension into sharp focus, raising a critical question for every founder in the healthcare and biotech space: where does innovation end and medical practice begin?
Sequenom Inc, along with another applicant, found itself at a crossroads when the Assistant Controller of Patents and Designs rejected their patent application numbered 3139/DELNP/2012. The rejection was grounded in Section 3(i) of the Patents Act, 1970, a provision that excludes certain methods from patentability. Section 3(i) specifically deals with inventions related to diagnostic methods, making it a particularly sensitive area for any medical or biotech innovation. Determined to protect their invention, Sequenom Inc appealed the decision, setting the stage for a high-stakes legal showdown over the nature and scope of their technology.
At the heart of the dispute was a fundamental disagreement about what Sequenom's invention actually was. The appellants argued that their creation was a screening test, not a diagnostic test. This distinction was not merely semantic; it was the crux of whether the invention fell within the prohibited territory of Section 3(i). On the other side, the respondent, the Controller of Patents, leaned on the broad definition of 'Pre-Natal Diagnostic Test' as outlined under the PCPNDT Act (Pre-Conception and Pre-Natal Diagnostic Techniques Act). By invoking this wider definition, the respondent sought to classify Sequenom's invention within the realm of diagnostic testing, thereby justifying the rejection under Section 3(i). The legal friction was clear: one side saw innovation in screening, while the other saw a diagnostic method in disguise.
As of the latest proceedings on 17 May 2022, the matter remains pending before the court. The central legal question continues to revolve around whether the invention qualifies as a screening test or a diagnostic test under the framework of Section 3(i) of the Patents Act, 1970, and how the PCPNDT Act's definition of pre-natal diagnostic tests should be interpreted in the context of patent eligibility. The court's eventual reasoning will likely hinge on how strictly or broadly it interprets the term 'diagnostic' and whether the PCPNDT Act's expansive definition should govern patentability determinations.
For founders and IP professionals in the medical and biotech space, this case serves as a powerful reminder: precision in describing your invention is not just good practice, it is a legal necessity. When filing patent applications for medical tests, the language used to characterize the invention can make or break its patentability under Section 3(i). Founders must work closely with patent attorneys to clearly articulate whether their technology is a screening tool or a diagnostic method, and to anticipate how regulators might interpret that distinction under both the Patents Act and related legislation like the PCPNDT Act. In the patent world, the words you choose today can determine whether your innovation is protected tomorrow.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before Delhi High Court - Orders. Understanding the court's reasoning in Sequenom Inc vs The Controller Of Patents is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Cryomass LlcvsAssistant Controller Of Patents And Designs
Cryomass LLC filed an appeal challenging the Assistant Controller's order dated May 31, 2021, which refused Patent Application No. 201917048279 titled "Cryogenic Separation of Plant Material". The refusal was based on non-fulfillment of requirements under Section 2(1)(ja) and claims falling within Section 3(f) of the Patents Act, 1970.
Japan Tobacco Inc.vsThe Assistant Controller of Patents and Designs, Government of India, Patent Office
Japan Tobacco Inc. filed a Transfer Civil Miscellaneous Appeal (Patents) challenging an earlier decision made by the Assistant Controller of Patents and Designs regarding its patent application. The appellant subsequently submitted a memo requesting the withdrawal of the appeal.
Glaxo Group LimitedvsAar Ess Remedies Private Limited & Ors
The Delhi High Court ruled in favor of Glaxo Group Limited against Aar Ess Remedies Private Limited & Ors for trademark, trade dress, and copyright infringement. The court found that the defendants were infringing on registered trademarks (ZINACEF, FORTAM) and common law rights (FORTAZ), as well as passing off the plaintiff's goods using similar packaging (trade dress/copyright). Given the multiple violations, the court granted permanent injunctions and awarded compensatory and punitive damages of ₹20 lakhs to Glaxo Group.
The Regents of the University of California and AnrvsController General of Patents and Designs and Anr
This Original Application (OA) was transferred from the Intellectual Property Appellate Board (IPAB) to the Calcutta High Court following the enactment of the Tribunals Reform Act, 2021. The court directed the Commercial Appellate Division to issue notices and file a report before setting the matter for hearing.
Astrazeneca AbvsWestcoast Pharmaceutical Works Limited
The plaintiffs, Astrazeneca Ab, filed a suit alleging that the defendant, Westcoast Pharmaceutical Works Limited, was infringing their Indian Patent IN 297581, which covers the anticancer drug Osimertinib (marketed as Tagrisso). The plaintiffs claimed the defendant was soliciting large orders to manufacture and sell the infringing product without authorization.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.